Pharmaceuticals, Biotechnology and Life Sciences
iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF’s 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector.
Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.
Innate Pharma and Bristol-Myers Squibb have modified the clinical trial protocol for its ongoing Phase I/II trial evaluating the safety and tolerability of lirilumab in combination with Opdivo in patients with advanced refractory solid tumors.
Mylan has launched Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer’s Pristiq Tablets in U.S..
The popularity of cannabis in its raw form will increasingly be priced as a commodity
Pharmaceutical Daily has conducted an interview with Duke Rodriguez, the CEO of Ultra Health, the company that has opened the first pharmaceutical cannabis factory in the USA.
The Ultra Health CEO answered questions about hurdles of a cannabis company, as most banks in the US cannot legally do business with such companies, and what is the new administration in the White House stand on legalizing cannabis.
Hikma Pharmaceuticals said on Friday that its US subsidiary West-Ward Pharmaceuticals Corp. has launched two doses of generic Pfizer’s Pristiq (Desvenlafaxine Succinate) ER Tablets.
Bristol-Myers Squibb has appointed Dr. Thomas J. Lynch, Jr. executive vice president and chief scientific officer, effective March 16, 2017.
Oxford BioDynamics has appointed a new Senior Vice President of Commercial Development to be based in the US. The new VP is Martin Reeves, who will take up this role in March 2017.
Servier has been cleared with Investiga New Drug (IND) by the U.S. Food and Drug Administration (FDA) for the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia.
U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine), seeking the addition of new clinical data evaluating VRAYLAR for the maintenance of efficacy in adults with schizophrenia to the current product label.